Rallybio Corp
Rallybio Corp (RLYB): 8 pipeline candidates · ~18 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
18.2 months
D/E 0.08 · 8% dilution
Lead: Phase 2
8 candidates
N/A
14 buys · 1 sell (180d)
A transparent, data-derived signal for Rallybio Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$92.3M
Cash
$41.3M
Quarterly Burn
$8.0M
Runway
18.2 mo
Revenue
$212K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$28.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 793,451 | $7.1M |
| viking global investors lp | 524,347 | $4.7M |
| balyasny asset management l.p. | 376,573 | $3.4M |
| laurion capital management lp | 302,756 | $2.7M |
| pivotal bioventure partners investment advisor llc | 300,579 | $2.7M |
| vanguard capital management llc | 224,080 | $2.0M |
| renaissance technologies llc | 156,527 | $1.4M |
| johnson & johnson | 152,901 | $1.4M |
| aju ib investment co., ltd. | 94,334 | $846K |
| mariner, llc | 50,566 | $454K |
Showing top 10 of 33 institutional holders of Rallybio Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Rallybio Corp's pipeline?
Rallybio Corp (RLYB) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Rallybio Corp's lead drug candidate?
Rallybio Corp's most advanced tracked candidate is anti- human monoclonal antibody (Phase 2) for Fetal and Neonatal Alloimmune Thrombocytopenia.
What is Rallybio Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Rallybio Corp has approximately 18.2 months of cash runway.
What is Rallybio Corp's market capitalization?
Rallybio Corp's market capitalization is approximately $92.3M.
Who is the CEO of Rallybio Corp?
Dr. Stephen Uden M.D., MBBS is the chief executive officer of Rallybio Corp (RLYB).
Get the full picture on Rallybio Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.